Trityl Irbesartan CAS 138402-10-5 Purity >98.0% (HPLC) Irbesartan Intermediate Factory

Short Description:

Chemical Name: Trityl Irbesartan

Synonyms: Triphenyl Irbesartan

CAS: 138402-10-5

Purity: >98.0% (HPLC)

Appearance: White to Off-White Powder

Intermediate of Irbesartan (CAS: 138402-11-6)

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Irbesartan Intermediates:
Irbesartan CAS 138402-11-6
Cyano-Irbesartan CAS 138401-24-8
Trityl Irbesartan CAS 138402-10-5
TTBB CAS 124750-51-2
Irbesartan Side Chain Hydrochloride CAS 151257-01-1

Chemical Properties:

Chemical Name	Trityl Irbesartan
Synonyms	Triphenyl Irbesartan; Irbesartan N1-Trityl Impurity; 2-Butyl-3-((2'-(2-trityl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1,3-diazaspiro[4.4]non-1-en-4-one; 2-Butyl-3-[[4-[2-(2-trityl-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
CAS Number	138402-10-5
CAT Number	RF-PI1893
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C44H42N6O
Molecular Weight	670.84
Density	1.20±0.10 g/cm3
Boiling Point	834.6±75.0℃ at 760 mmHg
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Powder
Purity / Analysis Method	>98.0% (HPLC)
Loss on Drying	<1.00%
Residue on Ignition	<0.50%
Single Impurity	<1.00%
Total Impurities	<2.00%
Heavy Metals	<20ppm
Infrared Spectrum	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Intermediate / Impurity of Irbesartan (CAS: 138402-11-6)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Trityl Irbesartan (CAS: 138402-10-5) is an intermediate or impurity of Irbesartan (CAS: 138402-11-6). Irbesartan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. Irbesartan was developed by Sanofi Research (now part of Sanofi-Aventis). It is jointly marketed by Sanofi-Aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.